MTSR - Metsera, Inc.
14.21
-2.240 -15.764%
Share volume: 1,453,943
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.05%
PREVIOUS CLOSE
CHG
CHG%
$16.45
-2.24
-0.14%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
-15.42%
1 Month
-43.23%
3 Months
-46.38%
6 Months
-46.38%
1 Year
-46.38%
2 Year
-46.38%
Key data
Stock price
$14.21
DAY RANGE
$13.78 - $17.00
52 WEEK RANGE
$13.78 - $32.81
52 WEEK CHANGE
-$46.38
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-26-2025
Company detail
CEO: Christopher Whitten Bernard
Region: US
Website: metsera.com
Employees: 81
IPO year: 2025
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: metsera.com
Employees: 81
IPO year: 2025
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
We are a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Our principal executive offices are located at 3 World Trade Center, 175 Greenwich Street, New York, New York.
Recent news
